EU medical device regulatory intelligence
Regulatory intelligence for MedTech operations is not just a feed of alerts and it is not a compliance verdict. It is a disciplined way to turn scattered public and internal signals into evidence a regulatory team can act on, with actor-role and duty-holder context intact.
ClinicOps applies machine breadth to find and classify signals and bounded human review to decide what they mean. RA/QA and the manufacturer retain regulatory decisions.
More signal is not the problem
Portfolio teams can already see EUDAMED records, certificate timing, Basic UDI-DI information, SS(C)P material and market-language documents. The harder problem is reconciling those inputs, preserving who is responsible for each, and deciding what deserves human review first.
Without that discipline, screening either overreaches into unsupported allegations or buries the real questions in noise.
Machine breadth. Human judgement. Evidence that survives review.
- Capture the signal — collect relevant public and supplied inputs across the bounded scope.
- Classify the evidence — separate screening signals, observations, source facts and unresolved questions from conclusions.
- Preserve actor-role and duty-holder context — keep manufacturer, authorised representative, importer and other relevant roles attached to the evidence.
- Block unsupported claims — never convert a missing field or structural signal into a compliance allegation.
- Prioritise the work — order the portfolio by what needs human review first.
- Deliver a reviewable action plan — hand RA/QA a queue with provenance and explicit uncertainty, not a verdict.
Duty-holder context matters
Under MDR Article 32, the manufacturer is the duty holder for drawing up the SS(C)P for applicable implantable and class III devices, subject to the Article 32 exclusions. ClinicOps preserves that context instead of flattening the workflow into generic document checking.
Public-register screening is an input, not a determination
Public-register screening is an evidence input, not a compliance determination or a claim of full-register coverage. A B-prefixed EUDAMED DI signal, for example, is useful for structural screening but does not by itself establish a device's full regulatory or SS(C)P state.
Where the method applies
Class III & implantable transition
Portfolio mapping, legacy-versus-MDR paths, certificate timing and SS(C)P duty questions.
EUDAMED intelligence
Turn legacy and MDR portfolio evidence into a prioritised transition work plan.
SS(C)P operations
Organise SS(C)P evidence, translations and operational handoffs while preserving duty-holder context.
Document control
Reconcile EUDAMED, IFU, labelling and market-language versions while RA/QA retains sign-off.
AR portfolio intelligence
Repeatable evidence and reconciliation support for multi-manufacturer portfolios.
Research & methods
See how ClinicOps separates public observations, evidence, limitations and operational interpretation.
What ClinicOps does not promise
Start with one bounded problem
Send a small portfolio export or discuss the workflow first. ClinicOps will identify what can be screened reproducibly, what evidence is missing and where human regulatory judgement is actually needed.